TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03044353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2398852 (anti-SAP mAb)
Description: Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2398852 (anti-SAP mAb)
Description: Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2398852 (anti-SAP mAb)
Description: Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
Study: NCT04001764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The radial artery cannulation over 2 cm of the wrist
Description: The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The radial artery cannulation in the distal 3/4 area of the forearm
Description: The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The radial artery cannulation in the distal 1/2 area of the forearm
Description: The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
Study: NCT05134389

Intervention type: PROCEDURE
Intervention: One Anastomosis Gastric Bypass
Description: Exposure to One Anastomosis Gastric Bypass

Intervention type: PROCEDURE
Intervention: One Anastomosis Gastric Bypass
Description: Exposure to One Anastomosis Gastric Bypass

Intervention type: PROCEDURE
Intervention: One Anastomosis Gastric Bypass
Description: Exposure to One Anastomosis Gastric Bypass
Study: NCT02230605

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Charlson Comorbidity Index
Description: To be completed at the Screening Visit and at POD 90

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form 36 Health Survey
Description: To be completed at the Screening Visit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Short Form 36 Health Survey
Description: To be completed at the Screening Visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Confusion Assessment Method
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memorial Delirium Assessment Scale
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Memorial Delirium Assessment Scale
Description: To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Quality of Recovery Scale
Description: To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative Quality of Recovery Scale
Description: To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
Study: NCT03192163

Intervention type: OTHER
Intervention: Survey
Description: 31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.

Intervention type: OTHER
Intervention: Survey
Description: 31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
Study: NCT04400890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol vs placebo given for 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 IU given on day one.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 100,000 IU given on day one.
Study: NCT04754035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: venetoclax 20 mg, 50 mg, 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imbruvica Oral Product
Description: Imbruvica 140 mg
Study: NCT01956591

Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.

Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.

Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.

Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.

Intervention type: DRUG
Intervention: Oxybutynin
Description: All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
Study: NCT02102191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: smoking cigarette without tobacco
Study: NCT01191684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02102191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-cigarette
Description: smoking cigarette without tobacco

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cigarette
Description: smoking cigarette with tobacco

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cigarette
Description: smoking cigarette with tobacco
Study: NCT03374176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500 mg / Metronidazole 250 mg
Description: Subjects were instructed to take a capsule three times a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Description: Subjects were instructed to take a capsule three times a day for 7 days
Study: NCT03725969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow milk
Description: Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
Study: NCT02087553

Intervention type: BIOLOGICAL
Intervention: Transfusion of red blood cells
Description: (non-experimental) PRBC transfusion
Study: NCT01191684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT03147027

Intervention type: OTHER
Intervention: medication
Description: medication to prevent sustained VT and ICD therapies
Study: NCT00262704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulated case-based customized learning
Description: Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulated case based customized learning + leader feedback
Description: Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
Study: NCT00543647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01539629

Intervention type: DEVICE
Intervention: Cardiac pacing
Description: Cadiac pacing via a pulse generator and implaned intracardiac leads.
Study: NCT01449825

Intervention type: DRUG
Intervention: Pazopanib use
Description: Treatment with pazopanib

Intervention type: DRUG
Intervention: Pazopanib use
Description: Treatment with pazopanib

Intervention type: DRUG
Intervention: Pazopanib use
Description: Treatment with pazopanib

Intervention type: DRUG
Intervention: Pazopanib use
Description: Treatment with pazopanib

Intervention type: DRUG
Intervention: Use of sunitinib, bevacizumab, or sorafenib
Description: Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib

Intervention type: DRUG
Intervention: Use of sunitinib, bevacizumab, or sorafenib
Description: Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
Study: NCT02843386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy by Fotemustin
Description: Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.

Intervention type: OTHER
Group type: OTHER
Intervention: Intensive surveillance
Description: Intensive surveillance~* Total duration: 3 years.~* liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months.
Study: NCT01127360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal injections
Study: NCT01449825

Intervention type: DRUG
Intervention: Use of sunitinib, bevacizumab, or sorafenib
Description: Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
Study: NCT01318616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training of the hip adductors
Description: Adductor strength training
Study: NCT03511339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TecTraum device
Description: A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck.
Study: NCT02580058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: 10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: 10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLD
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
Study: NCT02201810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate reduction intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recycling Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive QL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive QL

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive QL
Study: NCT03578406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV E6-specific TCR-T cells
Description: Patients were infused with HPV E6-specific TCR-T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV E6-specific TCR-T cells
Description: Patients were infused with HPV E6-specific TCR-T cells
Study: NCT01127360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injections
Study: NCT04126668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 with fed or fasting
Description: The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082 with fed or fasting
Description: The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
Study: NCT02350205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Self assembled skin substitute (SASS)
Description: All patients in Phase B will receive Self assembled skin substitute (SASS)
Study: NCT03615534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyle Changes
Description: Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wax Matrix Extended Release Niacin (WMER Niacin)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wax Matrix Extended Release Niacin (WMER Niacin)
Study: NCT01191684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified vaccinia virus ankara vaccine expressing p53
Description: Given SC
Study: NCT04162275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finamine tablets
Description: taken Finamine tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: taken Placebo tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: taken Placebo tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: taken Placebo tablets orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: taken Placebo tablets orally
Study: NCT03745469

Intervention type: DEVICE
Intervention: Smartphone
Description: A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)

Intervention type: DEVICE
Intervention: Smartphone
Description: A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
Study: NCT00327132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Clarithromycin
Study: NCT00932802

Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
Study: NCT01339182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-Somatropin
Description: Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
Study: NCT03267589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Description: Three different combination are being tested. Each cohort has different combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Description: Three different combination are being tested. Each cohort has different combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Description: Three different combination are being tested. Each cohort has different combination
Study: NCT02537470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic Remogliflozin Etabonate
Description: Experimental Drug

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01011283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: decitabine 20 mg/m\^2 /day intravenous (IV) infusion for 5 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: azacitidine 75 mg/m\^2 /day subcutaneous (SC) injection for 7 days every 28 days
Study: NCT03528577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zero-dose
Description: Treatment A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zero-dose
Description: Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zero-dose
Description: Treatment A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zero-dose
Description: Treatment A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of PROAIR® HFA
Description: Treatment B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 180 mcg of 90 mcg of PROAIR® HFA
Description: Treatment C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 90 mcg of albuterol sulfate inhalation aerosol
Description: Treatment D